Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Indivior Company

INDV.L
GB00BRS65X63
A12FHW

Price

7.53
Today +/-
-0.07
Today %
-1.04 %
P

Indivior stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Indivior stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Indivior stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Indivior stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Indivior's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Indivior Stock Price History

DateIndivior Price
10/11/20247.53 undefined
10/10/20247.61 undefined
10/9/20249.38 undefined
10/8/20249.82 undefined
10/7/202410.26 undefined
10/4/202410.30 undefined
10/3/20249.79 undefined
10/2/202410.02 undefined
10/1/20249.66 undefined
9/30/20249.85 undefined
9/27/20249.94 undefined
9/26/20249.57 undefined
9/25/20249.25 undefined
9/24/20249.19 undefined
9/23/20249.08 undefined
9/20/20249.39 undefined
9/19/20249.73 undefined
9/18/20249.58 undefined
9/17/20249.58 undefined
9/16/20249.59 undefined

Indivior Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Indivior, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Indivior from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Indivior’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Indivior. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Indivior’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Indivior’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Indivior’s growth potential.

Indivior Revenue, EBIT and net profit per share

DateIndivior RevenueIndivior EBITIndivior Net Income
2028e1.87 B undefined715.08 M undefined586.3 M undefined
2027e1.72 B undefined621.66 M undefined498.62 M undefined
2026e1.37 B undefined405.16 M undefined349.29 M undefined
2025e1.24 B undefined331.23 M undefined276.86 M undefined
2024e1.2 B undefined266.76 M undefined236.45 M undefined
20231.09 B undefined270 M undefined2 M undefined
2022901 M undefined223 M undefined-53 M undefined
2021791 M undefined206 M undefined205 M undefined
2020647 M undefined88 M undefined-148 M undefined
2019785 M undefined202 M undefined134 M undefined
20181.01 B undefined332 M undefined275 M undefined
20171.09 B undefined193 M undefined58 M undefined
20161.06 B undefined149 M undefined35 M undefined
20151.01 B undefined346 M undefined228 M undefined
20141.12 B undefined562 M undefined403 M undefined
20131.22 B undefined695 M undefined489 M undefined
20121.34 B undefined884 M undefined607 M undefined
20111.25 B undefined872 M undefined614 M undefined

Indivior Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
1.251.341.221.121.011.061.091.010.790.650.790.91.091.21.241.371.721.87
-6.78-9.19-8.31-9.064.343.31-8.05-21.89-17.5822.2613.9121.319.423.6810.4825.698.36
93.5492.9891.4591.4890.4389.8990.4887.2682.1785.7883.9483.1383.81-----
1.171.251.111.020.920.950.990.880.650.560.660.750.9200000
87288469556234614919333220288206223270266331405621715
69.5466.0257.1550.4034.1214.0817.6633.0325.7313.6026.0424.7524.7022.2426.6929.5636.0638.32
6146074894032283558275134-148205-532236276349498586
--1.14-19.44-17.59-43.42-84.6565.71374.14-51.27-210.45-238.51-125.85-103.7711,700.0016.9526.4542.6917.67
736.5736.5736.5723.88733.09148.64149.7150.23151.07146.57154.23139.01141.800000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Indivior Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Indivior is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
2011201220132014201520162017201820192020202120222023
                         
0.010.030.010.330.470.690.860.921.060.861.10.890.41
258273169162169205257269192179202220254
15029254038491271350
3234364148415278739395114142
17171422121215923503227457
0.330.350.230.570.720.991.231.331.361.191.441.261.26
11131313322754571071039585117
000000000009841
017120001533508284189
13511794916283928472628270237
0000000000000
8461797812210958446397127239287
230208198182216219219218292344388510691
0.560.560.430.750.941.211.441.551.651.531.831.771.95
                         
001.441.440.070.070.070.070.070.070.070.070.07
00000025567811
255142-1,503-1,896-328-345-263201541614614-44
-130-16-23-22-14-32-23-13-20-39-35
0000000000000
254145-66-475-279-295-2036620982203510
363554292733404739201373667
686573354501625625674584504583581676
2012963246241271184931106373391550
0000000000000
000173410154912111112
0.310.40.450.460.61.030.850.820.740.60.81.021.31
000719571434477237284273275266270
0000000000000
01641414240316426417577550433379
01641760613474793663701850825699649
0.310.410.491.221.221.51.651.481.441.451.631.721.95
0.560.560.430.750.941.211.441.551.651.531.831.771.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Indivior provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Indivior's financial health and stability.

Assets

Indivior's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Indivior must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Indivior after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Indivior's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
872884695562346149193292178-156213-85-4
25272826321413402826222128
0000000000000
-265-15468-135-71233675-56-6413959-328
831090-13131122-3411-211-11
00024444236251720182432
16411710359131633316-1834175733
715866791440320407295303151-193353-4-315
-25-3-3-26-31-35-43-41-7-4-34-6-53
-25-3-3-26-31-35-43-4-2-4-14-223-98
0000000375020-217-45
0000000000000
000759-121-78-86-240-13-116-12-17
0000002301-100-88-29
-697-845-806-90-144-147-84-237-13-10-94-100-46
-697.00-845.00-567.00----------
00-239-239-23-690000000
-718-1832413622517161136-202244-328-458
690863788414289372252262144-197319-10-368
0000000000000

Indivior stock margins

The Indivior margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Indivior. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Indivior.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Indivior's sales revenue. A higher gross margin percentage indicates that the Indivior retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Indivior's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Indivior's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Indivior's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Indivior. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Indivior's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Indivior Margin History

Indivior Gross marginIndivior Profit marginIndivior EBIT marginIndivior Profit margin
2028e83.81 %38.32 %31.42 %
2027e83.81 %36.1 %28.96 %
2026e83.81 %29.57 %25.5 %
2025e83.81 %26.71 %22.33 %
2024e83.81 %22.29 %19.75 %
202383.81 %24.7 %0.18 %
202283.13 %24.75 %-5.88 %
202183.94 %26.04 %25.92 %
202085.78 %13.6 %-22.87 %
201982.17 %25.73 %17.07 %
201887.26 %33.03 %27.36 %
201790.48 %17.66 %5.31 %
201689.89 %14.08 %3.31 %
201590.43 %34.12 %22.49 %
201491.48 %50.4 %36.14 %
201391.45 %57.15 %40.21 %
201292.98 %66.02 %45.33 %
201193.54 %69.54 %48.96 %

Indivior Stock Sales Revenue, EBIT, Earnings per Share

The Indivior earnings per share therefore indicates how much revenue Indivior has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Indivior earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Indivior's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Indivior’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Indivior's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Indivior Revenue, EBIT and net profit per share

DateIndivior Sales per ShareIndivior EBIT per shareIndivior Earnings per Share
2028e14.4 undefined0 undefined4.52 undefined
2027e13.29 undefined0 undefined3.85 undefined
2026e10.57 undefined0 undefined2.7 undefined
2025e9.57 undefined0 undefined2.14 undefined
2024e9.24 undefined0 undefined1.82 undefined
20237.71 undefined1.9 undefined0.01 undefined
20226.48 undefined1.6 undefined-0.38 undefined
20215.13 undefined1.34 undefined1.33 undefined
20204.41 undefined0.6 undefined-1.01 undefined
20195.2 undefined1.34 undefined0.89 undefined
20186.69 undefined2.21 undefined1.83 undefined
20177.3 undefined1.29 undefined0.39 undefined
20167.12 undefined1 undefined0.24 undefined
20151.38 undefined0.47 undefined0.31 undefined
20141.54 undefined0.78 undefined0.56 undefined
20131.65 undefined0.94 undefined0.66 undefined
20121.82 undefined1.2 undefined0.82 undefined
20111.7 undefined1.18 undefined0.83 undefined

Indivior business model

Indivior PLC is a globally operating company that specializes in the development and marketing of therapies for the treatment of addiction disorders. The company is headquartered in Slough, UK, and employs around 900 people worldwide. Indivior's history dates back to the founding of Reckitt Benckiser Pharmaceuticals in 1994. However, in 2014, the company decided to spin off its pharmaceutical division and continue as an independent company. Since then, Indivior has continuously invested in research and development to develop new and innovative therapies for the treatment of opioid addiction and other addiction disorders. Indivior's business model is based on ensuring comprehensive patient care for those suffering from addiction disorders through close collaboration with health authorities, doctors, and other healthcare professionals. The company relies on a combination of medical therapies and psychosocial support. Indivior operates in various divisions that focus on different aspects of addiction treatment. The key divisions are: - Opioid addiction: Indivior offers various therapies for the treatment of opioid addiction, including Suboxone Film and Sublocade, both based on buprenorphine. - Alcohol addiction: Indivior has also developed a therapy for the treatment of alcohol addiction marketed under the name ALO-02. - Pain therapy: Indivior has also developed a range of pain therapies based on buprenorphine or naloxone. - Research and development: A major focus of Indivior is on researching and developing new therapies for the treatment of addiction disorders. Indivior has also formed partnerships with other companies and organizations in the healthcare industry to improve the care of patients with addiction disorders. This includes collaboration with patient organizations advocating for the interests of patients with addiction disorders. Overall, Indivior has achieved impressive success in developing innovative therapies for the treatment of addiction disorders in recent years. The company has not only strengthened its position as a leading provider of opioid therapies, but also made progress in other areas such as alcohol addiction and pain therapy. However, Indivior has also faced challenges. For example, the company had to address allegations related to the marketing of Suboxone Film and other products. However, Indivior has taken steps to improve its compliance procedures and ensure that its products are marketed in accordance with applicable regulations. Overall, Indivior remains a leading provider of therapies for the treatment of addiction disorders and is committed to improving the quality of life for patients with addiction problems. Indivior is one of the most popular companies on Eulerpool.com.

Indivior SWOT Analysis

Strengths

Indivior PLC possesses several strengths that contribute to its strong market position and competitive advantage. These strengths include:

  • Strong brand reputation and recognition in the pharmaceutical industry.
  • Extensive portfolio of high-quality products and treatments.
  • Strong research and development capabilities, driving innovation and new product development.
  • Effective distribution networks and partnerships, ensuring broad market reach.
  • Strong financial performance and stability, providing a solid foundation for growth.

Weaknesses

Despite its strengths, Indivior PLC also experiences certain weaknesses that need to be addressed for sustained growth and success. These weaknesses include:

  • Dependency on a limited number of key products, increasing vulnerability to market fluctuations and patent expirations.
  • Legal and regulatory challenges, particularly related to intellectual property rights and patent disputes.
  • Reliance on a specific demographic, potentially limiting market diversification.

Opportunities

Indivior PLC can leverage various opportunities in the market to sustain growth and expand its market presence. These opportunities include:

  • Growing demand for pharmaceutical products, driven by an aging population and increasing healthcare needs.
  • Expansion into emerging markets with large untapped customer bases.
  • Strategic collaborations and partnerships to enhance product offerings and market reach.
  • Investment in technological advancements to improve drug delivery systems and patient outcomes.

Threats

Indivior PLC faces certain external threats that can impact its business operations and market position. These threats include:

  • Intense competition from existing pharmaceutical companies, potentially leading to price wars and margin pressures.
  • Increasing regulations and government policies that may impact the pricing and reimbursement of pharmaceutical products.
  • Risks of patent expirations, leading to generic competition and loss of market exclusivity.
  • Emerging technologies and disruptive innovations that may render existing products or treatments obsolete.

Indivior Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Indivior historical P/E ratio, EBIT multiple, and P/S ratio

Indivior shares outstanding

The number of shares was Indivior in 2023 — This indicates how many shares 141.8 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Indivior earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Indivior's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Indivior’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Indivior's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Indivior stock splits

In Indivior's history, there have been no stock splits.

Indivior dividend history and estimates

In 2023, Indivior paid a dividend amounting to 0 USD. Dividend means that Indivior distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Indivior provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Indivior’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Indivior's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Indivior Dividend History

DateIndivior Dividend
20160.07 undefined
20150.12 undefined

Indivior dividend payout ratio

In 2023, Indivior had a payout ratio of 33.62%. The payout ratio indicates the percentage of the company's profits that Indivior distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Indivior represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Indivior could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Indivior's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Indivior Payout Ratio History

DateIndivior Payout ratio
2028e33.57 %
2027e33.57 %
2026e33.58 %
2025e33.56 %
2024e33.57 %
202333.62 %
202233.48 %
202133.63 %
202033.74 %
201933.06 %
201834.09 %
201734.09 %
201631 %
201537.17 %
201434.09 %
201334.09 %
201234.09 %
201134.09 %
Unfortunately, there are currently no price targets and forecasts available for Indivior.

Indivior latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0.44  (0 %)2024 Q2
3/31/20240 0.37  (0 %)2024 Q1
12/31/20230 0.43  (0 %)2023 Q4
9/30/20230 0.34  (0 %)2023 Q3
6/30/20230 0.39  (0 %)2023 Q2
12/31/20180.35 0.45  (27.3 %)2018 Q4
9/30/20180.25 0.6  (137.62 %)2018 Q3
6/30/20180.45 0.45  (-0.99 %)2018 Q2
12/31/20170.35 0.35  (-0.99 %)2017 Q4
9/30/20170.45 0.35  (-22.99 %)2017 Q3
1
2

Eulerpool ESG Scorecard© for the Indivior stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

34

👫 Social

76

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
3,433
Scope 2 - Indirect emissions from purchased energy
1,531
Scope 3 - Indirect emissions within the value chain
1,194
Total CO₂ emissions
4,964
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Indivior shareholders

%
Name
Stocks
Change
Date
5.42436 % BlackRock Investment Management (UK) Ltd.7,028,620-26,8633/1/2024
5.12710 % SG Americas Securities, L.L.C.6,643,439-382,7614/4/2024
5.00200 % Société Générale Securities Services S.A.6,481,341-1,370,8644/12/2024
4.85395 % Scopia Capital Management LP6,289,509-3,301,4123/19/2024
4.53283 % The Vanguard Group, Inc.5,873,41452,83612/31/2023
3.56984 % Madison Avenue Partners LP4,625,61903/1/2024
3.45468 % Fidelity Management & Research Company LLC4,476,399-368,18112/31/2023
3.39066 % Goldman Sachs International4,393,4494,316,16812/31/2023
2.44912 % Sirovich (Matthew I.)3,173,4493,173,44912/31/2023
2.03332 % BofA Global Research (US)2,634,669-67,18612/31/2023
1
2
3
4
5
...
10

Indivior Executives and Management Board

Mr. Mark Crossley
Indivior Chief Executive Officer, Executive Director (since 2017)
Compensation 10.69 M
Mr. Ryan Preblick
Indivior Chief Financial Officer, Executive Director (since 2020)
Compensation 2.32 M
Mr. Graham Hetherington59
Indivior Non-Executive Independent Chairman of the Board
Compensation 396,935
Mr. Peter Bains66
Indivior Non-Executive Independent Director
Compensation 122,689
Ms. Juliet Thompson
Indivior Senior Non-Executive Independent Director
Compensation 122,689
1
2
3
4

Indivior Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Emergent BioSolutions Stock
Emergent BioSolutions
SupplierCustomer0,880,73-0,20-0,63-0,87-0,84
HLS Therapeutics Stock
HLS Therapeutics
SupplierCustomer0,590,38-0,18-0,31-0,56-0,38
Abrdn Stock
Abrdn
SupplierCustomer0,390,54-0,06-0,81-0,90-0,66
Jupiter Fund Management Stock
Jupiter Fund Management
SupplierCustomer0,340,65--0,68-0,85-0,50
DURECT Stock
DURECT
SupplierCustomer0,040,37-0,67-0,76-0,88-0,91
Evotec Stock
Evotec
SupplierCustomer-0,420,080,22-0,77-0,550,36
Aquestive Therapeutics Stock
Aquestive Therapeutics
SupplierCustomer-0,530,42-0,52-0,66-0,45-0,66
C4X Disc Hldgs Stock
C4X Disc Hldgs
SupplierCustomer-0,620,250,60-0,66-0,190,35
Addex Therapeutics Stock
Addex Therapeutics
SupplierCustomer-0,690,01-0,19-0,71-0,87-0,87
Aelis Farma Stock
Aelis Farma
SupplierCustomer-0,86-----
1

Most common questions regarding Indivior

What values and corporate philosophy does Indivior represent?

Indivior PLC represents values of innovation, integrity, and patient-focused care. The company's corporate philosophy centers around providing effective medical solutions for individuals suffering from opioid addiction. Indivior is committed to developing and delivering breakthrough treatments that help patients achieve and sustain recovery, while also addressing the societal impact of addiction. With a strong focus on research and development, the company continuously strives to improve patient outcomes and empower healthcare providers with the tools needed to combat opioid dependence. Indivior PLC's dedication to its mission and relentless pursuit of excellence make it a leading player in the pharmaceutical industry.

In which countries and regions is Indivior primarily present?

Indivior PLC is primarily present in multiple countries and regions around the world. The company has a strong global presence, with operations and markets in countries such as the United States, United Kingdom, Germany, Canada, France, Italy, Spain, and Australia. With its focus on developing and delivering innovative treatment solutions, Indivior PLC serves patients in these countries and regions, improving their quality of life and providing them with necessary healthcare support.

What significant milestones has the company Indivior achieved?

Indivior PLC has achieved several significant milestones since its establishment. The company gained regulatory approval for its ground-breaking medication, Suboxone®, which is used for the treatment of opioid dependence. Additionally, Indivior expanded its global reach and presence, establishing subsidiaries in key markets such as the United States, Canada, Australia, and Germany. The company's commitment to research and development led to the successful launch of new treatments and formulations, further enhancing patient outcomes. Indivior PLC continues to innovate and collaborate with healthcare professionals and stakeholders, aiming to address the evolving needs of individuals affected by addiction and related disorders.

What is the history and background of the company Indivior?

Indivior PLC is a pharmaceutical company specializing in providing addiction treatment solutions. With a rich history spanning over two decades, Indivior PLC was established in 2014 as a spin-off from its parent company, Reckitt Benckiser Group. Initially focused on the development of opioid addiction treatments, Indivior PLC quickly became a leader in the field thanks to its innovative products and extensive research. Today, the company maintains a global presence, serving patients in over 40 countries. Indivior PLC's commitment to improving the lives of individuals suffering from addiction has made it a trusted name in the healthcare industry.

Who are the main competitors of Indivior in the market?

The main competitors of Indivior PLC in the market are Reckitt Benckiser Pharmaceuticals, Sun Pharmaceutical Industries Ltd, and Alkermes.

In which industries is Indivior primarily active?

Indivior PLC is primarily active in the pharmaceutical industry.

What is the business model of Indivior?

The business model of Indivior PLC revolves around developing and commercializing innovative treatments for addiction disorders. As a global specialty pharmaceutical company, Indivior focuses on providing evidence-based solutions to improve the quality of life for individuals suffering from opioid dependence and related co-morbidities. By leveraging its scientific expertise, the company offers a comprehensive portfolio of products and services that cater to the needs of patients, healthcare professionals, and payers. Indivior's commitment to research and development, along with its collaborative approach, helps to address the growing global epidemic of opioid addiction and advance patient care in this critical area of healthcare.

What is the P/E ratio of Indivior 2024?

The Indivior P/E ratio is 4.52.

What is the P/S ratio of Indivior 2024?

The Indivior P/S ratio is 0.89.

What is the Quality Investing of Indivior?

The Quality Investing for Indivior is 5/10.

What is the revenue of Indivior 2024?

The expected Indivior revenue is 1.2 B USD.

How high is the profit of Indivior 2024?

The expected Indivior profit is 236.45 M USD.

What is the business model of Indivior

Indivior PLC is a specialized pharmaceutical company based in Slough, United Kingdom. The company focuses on the development, manufacturing, and marketing of medications for addiction disorders. Its business model is based on three pillars: product portfolio, research and development, and market entry strategies. The company's product range includes a wide range of prescription drugs for the treatment of addiction disorders such as opioid dependence and alcoholism. It also works closely with leading scientific institutes and universities for continuous research and development. Indivior has a strong presence in North America and recently partnered with Alvogen to accelerate market entry into China. It also operates a comprehensive program to educate patients and medical professionals about addiction disorders and their treatment. Overall, Indivior's unique business model focuses on specialized solutions for addiction disorders and collaborations with external organizations, academic institutions, government agencies, and medical professionals to provide tailored products and services worldwide. It is a leader in addiction treatment and is expected to continue being successful by leveraging its strengths and focusing on new therapeutic options and segments.

What is the Indivior dividend?

Indivior pays a dividend of 0 USD distributed over payouts per year.

How often does Indivior pay dividends?

The dividend cannot currently be calculated for Indivior or the company does not pay out a dividend.

What is the Indivior ISIN?

The ISIN of Indivior is GB00BRS65X63.

What is the Indivior WKN?

The WKN of Indivior is A12FHW.

What is the Indivior ticker?

The ticker of Indivior is INDV.L.

How much dividend does Indivior pay?

Over the past 12 months, Indivior paid a dividend of 0.07 USD . This corresponds to a dividend yield of about 0.97 %. For the coming 12 months, Indivior is expected to pay a dividend of 0 USD.

What is the dividend yield of Indivior?

The current dividend yield of Indivior is 0.97 %.

When does Indivior pay dividends?

Indivior pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Indivior?

Indivior paid dividends every year for the past 5 years.

What is the dividend of Indivior?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Indivior located?

Indivior is assigned to the 'Health' sector.

Wann musste ich die Aktien von Indivior kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Indivior from 7/29/2016 amounting to 0.073 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2016.

When did Indivior pay the last dividend?

The last dividend was paid out on 7/29/2016.

What was the dividend of Indivior in the year 2023?

In the year 2023, Indivior distributed 0 USD as dividends.

In which currency does Indivior pay out the dividend?

The dividends of Indivior are distributed in USD.

All fundamentals about Indivior

Our stock analysis for Indivior Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Indivior Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.